progression-free

Pfizer's study found so-called "progression-free survival," the period of time that a patient's tumors don't grow and the disease didn't worsen, was 6.7 months on average in the group taking its drug, versus 4.7 months in the group taking Nexavar, also known as sorafenib.

Pfizer Kidney Drug Gains FDA Approval Joan E. Solsman 2012

The results showed that so-called "progression-free survival" was increased to an average 6.7 months compared with 4.7 months on sorafenib, which goes by the brand name Nexavar.

Pfizer Kidney Cancer Drug Gets FDA Panel's Nod Thomas M. Burton 2011

Rago: It's something called progression-free survival, which means how long these women survive without their disease spreading or getting worse.

Obama vs. the Jets 2011

Rago: It's something called progression-free survival, which means how long these women survive without their disease spreading or getting worse.

Obama vs. the Jets 2011

For those who received Avastin the median time before tumors worsened or the patient died - a measure known as progression-free survival - was 16.7 months, compared to 13.5 months for the control group, a difference that was statistically significant.

NYT > Home Page By ANDREW POLLACK 2011

But it did slow tumor growth, giving many patients a longer "progression-free" survival.

There's No 'Average' Cancer Patient Gregory Conko 2011

Rago: Well, sure, but the Cancer Drugs Division said, you need--we're going to approve this if you can show progression-free survival.

Obama vs. the Jets 2011

Avastin, over three rigorous clinical trials, did show progression-free survival.

Obama vs. the Jets 2011

But the drug's permanent approval hinged on the results of two additional clinical studies focusing on the progression-free survival end-point experienced by the majority of Avastin users.

There's No 'Average' Cancer Patient Gregory Conko 2011

As before, neither study found an increase in overall survival, but they did record modest gains in progression-free survival—about five and a half months longer than those on the alternative treatment.

There's No 'Average' Cancer Patient Gregory Conko 2011